The sooner cancer is diagnosed, the better the chance it can be treated. This is why, when it comes to melanoma, doctors advise people to regularly check their bodies and look out for new moles or existing ones that have changed shape.
Publications
Conventional RECIST Might Underestimate Pembrolizumab Benefit for Melanoma
Because of atypical responses, conventional Response Evaluation Criteria in Solid Tumors (RECIST) might underestimate the benefit of pembrolizumab in approximately 15% of patients treated for melanoma, a study published in the Journal of Clinical Oncology has shown.1
Expert Shares Challenges, Considerations When Using Immunotherapies in Melanoma
The field of melanoma recently gained an influx of immunotherapy approvals, and advancement in the field doesn’t seem to be slowing down.
When the FDA expanded the drug’s label in December 2015, pembrolizumab (Keytruda) became the first anti–PD-1 therapy approved for previously untreated patients with advanced melanoma, regardless of BRAF status.
Scientific Journals for February 2016
Sildenafil Potentiates a cGMP-Dependent Pathway to Promote Melanoma Growth Sandeep Dhayade, Susanne Kaesler, Tobias Sinnberg, Hyazinth Dobrowinski Stefanie Peters Ulrike Naumann He Liu Robert E. Hunger Martin Thunemann Tilo Biedermann Birgit…
Read More